What is Hexarelin?
Hexarelin (examorelin) is a synthetic six amino acid analog (modified version) of GHRP-6 that releases growth hormone through the ghrelin receptor (the receptor for the body's hunger hormone) and is active by intravenous, subcutaneous (under the skin), intranasal, and even oral routes. Small randomized studies in the 1990s showed strong acute GH release, but a 16 week study found the GH response declined substantially with continued use, no randomized trial tested it for the uses it is sold for, and development stopped without any approval. It is not on any FDA compounding list (the lists of raw ingredients pharmacies may use), is not FDA approved, and is prohibited by WADA.
Hexarelin is a synthetic hexapeptide growth hormone secretagogue (ghrelin receptor agonist), methylated analog of GHRP-6. It is also known as Examorelin, EP 23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, Hexarelin acetate.
How does it work?
Hexarelin activates the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons, releasing GH synergistically with GHRH and raising prolactin, ACTH, and cortisol. It also binds CD36 on cardiac and vascular cells, which is the basis of animal studies showing cardioprotection independent of GH. Methylation of the tryptophan residue makes it more stable than GHRP-6.
| Cluster | Metabolic and growth hormone axis |
|---|---|
| Routes | Intravenous (research studies); Subcutaneous injection (research studies and as sold); Intranasal and oral (research studies, lower bioavailability) |
| Conditions studied | Growth hormone deficiency and GH secretagogue use |
| Record | v3, reviewed, verified Sep 30, 2026 |
What does the evidence say about Hexarelin?
Three small randomized studies from the 1990s, each in 8 to 12 healthy volunteers and compared with placebo or saline, found that single intravenous doses of hexarelin raise growth hormone in a dose dependent way, along with prolactin, ACTH, and cortisol. These trials measured hormone responses over a few hours, not clinical outcomes. A 16 week study of twice daily injections found the GH response fell by about half and IGF-1 did not rise, and a four arm comparison with placebo in 24 bypass surgery patients found a single dose briefly improved measures of heart pumping. No randomized trial has tested hexarelin for muscle growth, fat loss, or any other use it is sold for.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 3 | 32 |
| Human observational studies | 6 | 24 |
| Animal studies | 0 | n/a |
| All indexed studies | 9 | 56 |
Human evidence
Ghigo 1994: hexarelin released GH in healthy volunteers by intravenous, subcutaneous, intranasal, and oral routes, with intravenous 1 to 2 ug/kg producing the largest response. Imbimbo 1994: a double blind, placebo controlled, rising dose study in 12 healthy men, with placebo randomly inserted into the sequence, found dose dependent GH release after single intravenous doses. Korbonits 1995: a double blind, randomized trial in 12 healthy volunteers gave hexarelin or placebo with or without naloxone; hexarelin raised GH, prolactin, ACTH, and cortisol, and naloxone did not change the GH response. Loche 1997: 8 healthy men received saline or hexarelin in random order in the morning and during sleep, and GH rose in both settings. Loche 1995: GH release in short normal and obese children and reduced response in hypopituitary subjects. Arvat 1997: hexarelin and GHRP-2 released more GH than GHRH and raised prolactin, ACTH, and cortisol. Rahim 1998: 16 weeks of 1.5 ug/kg twice daily subcutaneous hexarelin in healthy adults led to a partial loss of the GH response and no sustained IGF-1 rise, with recovery after washout. Frieboes 2004: hexarelin decreased slow wave sleep and raised GH, ACTH, cortisol, and prolactin during sleep. Broglio 2002: a four arm comparison in 24 men with coronary artery disease during bypass surgery gave a single intravenous dose of hexarelin (2 ug/kg), GHRH, recombinant GH, or placebo; only hexarelin raised left ventricular ejection fraction, cardiac index, and cardiac output, for up to 90 minutes.
Animal evidence
Rodent studies show hexarelin protects the heart against ischemia and reperfusion injury and improves cardiac function after infarction, partly through CD36 binding rather than GH. Rat studies also show GH release and synergy with GHRH. These cardiac findings have not progressed to human outcome trials.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Growth hormone-releasing activity of hexarelin in humans. A dose-response study1994 PMID 7957536 | Double blind, placebo controlled, rising dose study of single intravenous boluses, with placebo randomly inserted into the sequencen = 12 Healthy adult men | Plasma GH rose dose dependently, peaking at about 30 minutes and returning to baseline within 240 minutes; hormone response only | Evidence: Human RCT evidence |
| The effect of an opiate antagonist on the hormonal changes induced by hexarelin1995 PMID 7586608 | Double blind, randomized trial of intravenous hexarelin or placebo, with or without naloxonen = 12 Healthy volunteers | Hexarelin raised GH, prolactin, ACTH, and cortisol but not TSH; naloxone did not change the GH response; hormone response only | Evidence: Human RCT evidence |
| Acute administration of hexarelin stimulates GH secretion during day and night in normal men1997 PMID 9156035 | Saline or intravenous hexarelin given in random order, in the morning and during nocturnal sleepn = 8 Healthy men aged 21 to 33 | Peak GH after hexarelin was similar in the morning and during sleep, with a larger total GH response during sleep; hormone response only | Evidence: Human RCT evidence |
| Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man1994 PMID 8126144 | Dose finding pharmacology studyHealthy adult volunteers | GH release by all four routes; intravenous 1 to 2 ug/kg produced the largest response | Evidence: Human observational evidence |
| Growth hormone status during long-term hexarelin therapy1998 PMID 9589671 | 16 week open treatment study with washoutHealthy adults given 1.5 ug/kg subcutaneously twice daily | GH response to hexarelin attenuated by about half over 16 weeks with no sustained IGF-1 rise; recovered after washout | Evidence: Human observational evidence |
| Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man1997 PMID 9285939 | Crossover pharmacology studyHealthy young adults | Hexarelin released more GH than GHRH and raised prolactin, ACTH, and cortisol | Evidence: Human observational evidence |
| Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers2004 PMID 15177700 | Placebo controlled sleep laboratory studyHealthy volunteers | Reduced slow wave sleep; increased GH, ACTH, cortisol, and prolactin | Evidence: Human observational evidence |
| Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery2002 PMID 12144941 | Four arm controlled comparison of a single intravenous dose of hexarelin, GHRH, recombinant GH, or placebo; indexed in PubMed as a controlled clinical trial, randomization not stated in the abstractn = 24 Men with coronary artery disease undergoing bypass surgery under general anesthesia | Only hexarelin raised left ventricular ejection fraction, cardiac index, and cardiac output, lasting up to 90 minutes; GHRH, recombinant GH, and placebo had no hemodynamic effect | Evidence: Human observational evidence |
| The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency1995 PMID 7673411 | Pharmacology studyChildren and adults with GH deficiency | GH response present when pituitary function was intact and blunted in organic hypopituitarism | Evidence: Human observational evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Growth hormone deficiency and GH secretagogue use | Evidence: Human RCT evidence | Three small randomized studies in healthy volunteers found single intravenous doses raise growth hormone; these measured hormone responses over a few hours, not clinical outcomes; in a 16 week study the GH response fell by about half and IGF-1 did not rise; not approved. |
Is Hexarelin legal in the United States?
FDA and compounding status
Not FDA approved and never commercially developed to approval anywhere. Hexarelin does not appear on the FDA 503A or 503B bulks lists or in Category 2 as of the FDA pages current to April 2026, which means it has not been nominated and there is no federal basis for a compounding pharmacy to use it. It was not part of the April 2026 Category 2 withdrawals or the July 2026 advisory committee review.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
- WADA
WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times
The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.
Full tracker for Hexarelin or the category-wide tracker.
Email me when Hexarelin's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Hexarelin used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Acute studies used 1 to 2 ug/kg intravenously, 2 to 3 ug/kg subcutaneously, 20 ug/kg intranasally, and up to 20 mg orally in adults (Ghigo 1994). The only chronic study used 1.5 ug/kg subcutaneously twice daily for 16 weeks (Rahim 1998). No dose has been established for any therapeutic use.
Routes reported
| # | Route |
|---|---|
| 1 | Intravenous (research studies) |
| 2 | Subcutaneous injection (research studies and as sold) |
| 3 | Intranasal and oral (research studies, lower bioavailability) |
What are the side effects and interactions of Hexarelin?
Side effects
| # | Reported side effect |
|---|---|
| 1 | Rise in cortisol, ACTH, and prolactin with each dose |
| 2 | Loss of GH response with continued use (about 50% attenuation over 16 weeks) |
| 3 | Transient flushing and warmth after intravenous dosing |
| 4 | Reduced slow wave sleep in a controlled sleep study |
| 5 | Increased hunger (ghrelin mimetic effect) |
| 6 | No long term human safety data |
Interactions
| # | Interaction |
|---|---|
| 1 | Insulin and oral diabetes medications: GH secretagogues raise blood glucose |
| 2 | Glucocorticoids: additive cortisol exposure |
| 3 | GHRH analogs (sermorelin, CJC-1295): synergistic GH release, untested long term |
| 4 | No formal human drug interaction studies exist |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Active cancer (theoretical GH and IGF-1 driven tumor growth) |
| 2 | Diabetes or impaired glucose tolerance without monitoring |
| 3 | Pregnancy and breastfeeding (no data) |
| 4 | Athletes subject to WADA testing (prohibited at all times under S2) |
How do people access Hexarelin legally?
Typical cost: Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Not available
No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.
Not available
Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Hexarelin
What's actually offered, and what that means for you
FDA has found an ingredient distributor offering hexarelin anyway. [11]
Being offered does not change the legal status of hexarelin. Hexarelin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [7] [8]
What FDA found
- December 2025: FDA cited a defect in a bulk ingredient distributor's drug listing for hexarelin acetate. The letter does not say hexarelin went to compounders. [11]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [12] [13] [14] [15] [16]
What that means for you
- A pharmacy that compounds hexarelin is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [12] [13]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [16]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [17]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [18] [19]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [8]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, hexarelin is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [9]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound hexarelin, with or without a prescription. [7]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [20] [21] [22]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [22] [23] [24]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [16] [25] [26] [27] [28] [29]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [16]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [20]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [24]
- Pharmacy: Is this made for me on a prescription written in my name? [23]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [22] [24]
- Prescriber: What is the legal basis for a pharmacy to compound hexarelin? Is it FDA approved or on the 503A bulks list? [7] [16]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [24]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [17]
Frequently asked questions
Is hexarelin legal in the United States?
It is not FDA approved and is not on any FDA compounding list (the lists of raw ingredients pharmacies may use to custom-make drugs), so no licensed pharmacy can lawfully compound it. It has never been approved in any country. Possession is not a crime, but selling it for human use is unlawful: research chemical products are unapproved drugs. [7] [8] [10]
Does hexarelin work to raise growth hormone?
Acutely, yes, and strongly: intravenous 1 to 2 ug/kg produced larger GH peaks than GHRH in healthy adults, and it worked by subcutaneous, intranasal, and oral routes. The catch is tolerance. In the only 16 week study, the GH response to twice daily injections fell by about half and IGF-1 did not stay elevated, which is one reason development stopped. [1] [2] [3]
What are the side effects of hexarelin?
Each dose raises cortisol, ACTH, and prolactin along with GH, and a controlled sleep study found it reduced slow wave sleep. Flushing after intravenous dosing and hunger are reported. The GH response fades with continued use. No long term human safety data exist. [2] [3] [4]
How is hexarelin taken?
In published studies it was given intravenously (1 to 2 ug/kg), subcutaneously (2 to 3 ug/kg, or 1.5 ug/kg twice daily in the chronic study), intranasally, and orally at high doses. Products sold online are subcutaneous injection vials. No therapeutic dosing schedule has been established. [1] [2]
How much does hexarelin cost?
There is no licensed US price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [8] [10]
Is hexarelin banned by WADA?
Yes. Growth hormone secretagogues including hexarelin (examorelin) are prohibited at all times under section S2 of the WADA Prohibited List. [9]
Hexarelin vs GHRP-6: what is the difference?
Hexarelin is GHRP-6 with a methylated tryptophan, which makes it more stable and, in head to head human studies, a somewhat more potent GH releaser. Both raise cortisol and prolactin and both stimulate hunger. GHRP-6 was placed in FDA 503B Category 2 in September 2023 while hexarelin has never been nominated at all. Neither has long term outcome data. [6] [8]
Does hexarelin protect the heart?
In rodents, hexarelin reduces ischemia and reperfusion injury through CD36 binding independent of GH. In humans, a four arm comparison with placebo in 24 bypass surgery patients found a single intravenous dose briefly improved measures of heart pumping. No trial has tested repeated dosing for any cardiac condition, so the cardioprotection claim is animal level evidence. [5]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Ghigo E et al. Growth hormone-releasing activity of hexarelin after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 1994PubMed 8126144, 1994
- [2]Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998PubMed 9589671, 1998
- [3]Arvat E et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man. Peptides 1997PubMed 9285939, 1997
- [4]Frieboes RM et al. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology 2004PubMed 15177700, 2004
- [5]Broglio F et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur J Pharmacol 2002PubMed 12144941, 2002
- [6]Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998PubMed 9465289, 1998
- [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
- [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
- [9]WADA Prohibited List, section S2 peptide hormones, growth factors, related substances and mimeticsWADA, 2026
- [10]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). Hexarelin: evidence, legality, and access. https://peptideagent.ai/peptides/hexarelin- HTML link
<a href="https://peptideagent.ai/peptides/hexarelin">Hexarelin: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.